|
|
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
- Neddylation
- Potential therapeutics for SARS
- Regulation of HMOX1 expression and activity
- Heme signaling
- KEAP1-NFE2L2 pathway
- KEAP1-NFE2L2 pathway
- Nuclear events mediated by NFE2L2
- GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
- NFE2L2 regulating TCA cycle genes
- NFE2L2 regulating inflammation associated genes
- NFE2L2 regulating anti-oxidant/detoxification enzymes
- NFE2L2 regulates pentose phosphate pathway genes
- NFE2L2 regulating tumorigenic genes
- NFE2L2 regulating MDR associated enzymes
- NFE2L2 regulating ER-stress associated genes
- Regulation of NFE2L2 gene expression
- Regulation of NFE2L2 gene expression
- Regulation of PD-L1(CD274) transcription
|
|
|
|
|
NFKBIA |
NFKB inhibitor alpha |
- Activation of NF-kappaB in B cells
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- SUMOylation of immune response proteins
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- SARS-CoV-1 activates/modulates innate immune responses
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
- Acetylsalicylic acid
- Bardoxolone methyl
- Astaxanthin
|
- Hodgkin lymphoma
- Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
|
|
|
NHERF1 |
NHERF family PDZ scaffold protein 1 |
|
|
- Nephrolithiasis/osteoporosis, hypophosphatemic
|
|
|
NHERF2 |
NHERF family PDZ scaffold protein 2 |
|
|
|
|
|
NOS1 |
nitric oxide synthase 1 |
- ROS and RNS production in phagocytes
- Nitric oxide stimulates guanylate cyclase
- Ion homeostasis
|
- Citrulline
- Donepezil
- Ketamine
- L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide
- Formic acid
- 3-Bromo-7-Nitroindazole
- N-{(4S)-4-Amino-5-[(2-aminoethyl)amino]pentyl}-N'-nitroguanidine
- N-[3-(aminomethyl)benzyl]acetamidine
- L-N(omega)-nitroarginine-(4R)-amino-L-proline amide
- 1-hydroxy-2-isopropylguanidine
- 7-Nitroindazole
- N-omega-propyl-L-arginine
- 2-butyl-1-hydroxyguanidine
- S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
- N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine
- Flavin adenine dinucleotide
- Flavin mononucleotide
- N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide
- Nicotinamide adenine dinucleotide phosphate
- S-Ethyl-N-Phenyl-Isothiourea
- [(1S)-4-(1-Aminobutylideneamino)-1-carboxybutyl]azanium
- 5-N-Allyl-arginine
- Nitroarginine
- NXN-188
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine
- Methylene blue
|
|
|
|
NOXA1 |
NADPH oxidase activator 1 |
- RHO GTPases Activate NADPH Oxidases
- RAC1 GTPase cycle
- RAC3 GTPase cycle
- WNT5:FZD7-mediated leishmania damping
|
|
|
|
|
NR1H2 |
nuclear receptor subfamily 1 group H member 2 |
- PPARA activates gene expression
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- VLDLR internalisation and degradation
- NR1H2 & NR1H3 regulate gene expression linked to lipogenesis
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake
- NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose
- NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
|
- GW-3965
- Benzenesulfinic acid
- TO-901317
- 1,1,1,3,3,3-HEXAFLUORO-2-{4-[(2,2,2-TRIFLUOROETHYL)AMINO]PHENYL}PROPAN-2-OL
- Diacerein
- Rhein
|
|
|
|
NRGN |
neurogranin |
- Long-term potentiation
- Long-term potentiation
|
|
|
|
|
NUMB |
NUMB endocytic adaptor protein |
- Activated NOTCH1 Transmits Signal to the Nucleus
- Recycling pathway of L1
- Degradation of GLI1 by the proteasome
- Hedgehog 'on' state
- Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
|
|
|
|
|
OGG1 |
8-oxoguanine DNA glycosylase |
- Recognition and association of DNA glycosylase with site containing an affected pyrimidine
- Cleavage of the damaged pyrimidine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Cleavage of the damaged purine
- Displacement of DNA glycosylase by APEX1
- APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
- Defective OGG1 Substrate Binding
- Defective OGG1 Substrate Processing
|
|
|
|
|
OPRD1 |
opioid receptor delta 1 |
- Peptide ligand-binding receptors
- G alpha (i) signalling events
- Interleukin-4 and Interleukin-13 signaling
|
- Tramadol
- Morphine
- Codeine
- Amitriptyline
- Hydromorphone
- Methadone
- Oxycodone
- Dextromethorphan
- Butorphanol
- Dextropropoxyphene
- Naltrexone
- Sufentanil
- Fentanyl
- Loperamide
- Nalbuphine
- Levorphanol
- Remifentanil
- Buprenorphine
- Hydrocodone
- Diphenoxylate
- Naloxone
- Oxymorphone
- Ketamine
- Aripiprazole
- 3-Methylthiofentanyl
- Dimethylthiambutene
- Diamorphine
- Etorphine
- Carfentanil
- Diprenorphine
- Dihydromorphine
- 3-Methylfentanyl
- ADL5859
- Tapentadol
- Nalmefene
- Alvimopan
- Amisulpride
- Morphine glucuronide
- Ketobemidone
- Cannabidiol
- Butyrfentanyl
- Pholcodine
- Eluxadoline
- Opium
- Naldemedine
- Samidorphan
- Metenkefalin
- Medical Cannabis
- Nabiximols
- Loxicodegol
|
|
|
|
PA2G4 |
proliferation-associated 2G4 |
|
|
|
|
|
PAM |
peptidylglycine alpha-amidating monooxygenase |
|
- Ascorbic acid
- N-Alpha-Acetyl-3,5-Diiodotyrosylglycine
- N-alpha-Acetyl-3,5-diiodotyrosyl-D-threonine
|
|
|
|
PDLIM7 |
PDZ and LIM domain 7 |
|
|
|
|
|
PEA15 |
proliferation and apoptosis adaptor protein 15 |
- RAF-independent MAPK1/3 activation
- RAF/MAP kinase cascade
|
|
|
|
|
PEBP1 |
phosphatidylethanolamine binding protein 1 |
- MAP2K and MAPK activation
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
|
|
|
|
|
PFKFB1 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 |
- PKA-mediated phosphorylation of key metabolic factors
- PP2A-mediated dephosphorylation of key metabolic factors
- Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
- Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
|
- D-Gluco-2,5-Anhydro-1-Deoxy-1-Phosphonohexitol-6-Phosphate
- sn-glycerol 3-phosphate
- Adenosine 5'-[gamma-thio]triphosphate
- Guanosine-5'-Triphosphate
- Fructose-6-phosphate
|
|
|
|
PFKFB2 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 |
- Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
|
|
|
|
|
PHB2 |
prohibitin 2 |
- Processing of SMDT1
- Cellular response to mitochondrial stress
|
- Capsaicin
- Rocaglamide
- Didesmethylrocaglamide
|
|
|
|
PICK1 |
protein interacting with PRKCA 1 |
- Cell surface interactions at the vascular wall
- Trafficking of GluR2-containing AMPA receptors
|
|
|